2026-06-23 FDA Warning Letter: ketaminetroches.com Cited for Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
The short version: The FDA issued a Warning Letter (MARCS-CMS 725148, June 23, 2026) to ketaminetroches.com alleging violations of the Federal Food, Drug, and Cosmetic Act for introducing unapproved and misbranded ketamine products into interstate commerce, including "Ketamine Troches" marketed for mental health conditions without FDA approval. The agency states that while FDA-approved ketamine products exist as injectable formulations subject to specific controls, no approved applications exist for the troche products offered on the website, and the agency cites risks including product contamination, varying ingredient amounts, and serious adverse events absent medical supervision. The FDA requests cessation of sales of unapproved and misbranded drugs and warns that failure to address violations may result in seizure, injunction, or other regulatory action.
Argus analysis
# FDA Warning Letter Analysis: ketaminetroches.com
**Company and Violations**
Ketaminetroches.com, identified in FDA records as FEI 3043544217, received a warning letter from the Center for Drug Evaluation and Research (CDER) on June 23, 2026, for introducing unapproved and misbranded ketamine products into interstate commerce. The FDA conducted a website review on February 25, 2026, and documented violations related to "Ketamine Troches"—lozenges marketed for psychiatric conditions including anxiety and depression. The agency emphasized that the easy online availability of unapproved ketamine products poses serious consumer health risks, particularly given the lack of appropriate medical supervision and the potential for contamination, counterfeit formulations, or inconsistent active ingredients.
**Regulatory Citations**
The violations cite sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (codified at 21 U.S.C.). Section 505(a) requires FDA approval before new drugs enter commerce; the company lacked such approval. Section 502(f)(1) requires adequate directions for use that allow layperson safety—impossible for prescription psychiatric drugs. Section 503(b)(1) establishes that certain drugs require licensed practitioner supervision. The FDA noted that while FDA-approved ketamine (KETALAR, an injectable anesthetic) and esketamine (SPRAVATO, a nasal spray for treatment-resistant depression bearing a black box warning with mandatory REMS) exist, the troches offered lack equivalent regulatory oversight and medical supervision requirements.
**Timeline and Next Steps**
The recipient must respond in writing within 15 business days, detailing corrective actions and preventative measures. Compliance officers monitoring this sector should watch for cessation of sales, website takedown, or product reformulation claims. Failure to respond adequately may trigger seizure or injunction actions. Similar internet-based pharmaceutical operations should expect heightened FDA scrutiny of unapproved ketamine offerings, particularly psychiatric claims and direct-to-consumer marketing bypassing prescriber channels.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER ketaminetroches.com MARCS-CMS 725148 — June 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: ketaminetroches.com United States sales@ketaminetroches.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 23, 2026 WARNING LETTER Reference Number: MARCS-CMS 725148 To ketaminetroches.com: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.ketaminetroches.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.ketaminetroches.com introduces into interstate commerce unapproved and misbranded ketamine drug products, including certain drugs for which the FDA-approved version is an injectable or subject to a Risk Evaluation and Mitigation Strategy (REMS). 1 FDA has identified significant risks associated with unapproved ketamine products, especially in the absence of appropriate medical supervision. Given the increased interest in the use of ketamine products, the easy availability of unapproved and misbranded ketamine products via the internet puts U.S. consumers at risk for serious adverse events. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.ketaminetroches.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.ketaminetroches.com, FDA Establishment Identifier (FEI) 3043544217, on February 25, 2026. Violations of the Federal Food, Drug, and Cosmetic Act On your website at internet a…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has ketaminetroches.com had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for ketaminetroches.com as of 2026-07-07. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-06-23 FDA Warning Letter: ketaminetroches.com Cited for Unapproved New Drugs/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-ketaminetroches-com-2026-06-23-unapproved-drug
"2026-06-23 FDA Warning Letter: ketaminetroches.com Cited for Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-ketaminetroches-com-2026-06-23-unapproved-drug.
Argus HQ Research. "2026-06-23 FDA Warning Letter: ketaminetroches.com Cited for Unapproved New Drugs/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-ketaminetroches-com-2026-06-23-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_ketaminetroches_com_2026_06_23_unapproved_drug_2026,
title = {2026-06-23 FDA Warning Letter: ketaminetroches.com Cited for Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-ketaminetroches-com-2026-06-23-unapproved-drug},
note = {Accessed: July 13, 2026}
}